Company Index
BeiGene
BeiGene
NEWS
Hiring Ernst & Young in the U.S. may help but won’t work without a bilateral Sino-American accord on audit documents
Apr.8 2022 04:59 AM
With listing on STAR Market, loss-making cancer-drug developer would be the first Chinese biotech to trade shares on the mainland and in Hong Kong and New York
Nov.17 2021 05:11 AM
Eleven-year-old cancer-focused Chinese biotech turned its first profit this year after three of its drugs made China’s National Reimbursement Drug List
Jun.29 2021 06:18 AM
May.10 2021 18:28 PM
Dec.3 2020 18:17 PM
Beijing-based BeiGene will take over commercialization of three cancer medicines from American biopharmaceutical giant in China as part of deal, and work to commercialize 20 more
Nov.1 2019 18:25 PM
Nov.1 2019 10:16 AM
Top 15 listings by Chinese firms have raised $28.7 billion so far this year, led by China Tower this week
Aug.10 2018 17:18 PM
After lackluster BeiGene IPO, analysts argue share prices will rise when more products hit market
Aug.8 2018 18:45 PM
Hong Kong IPO could raise nearly $1 billion, complementing drug developer’s current Nasdaq listing
Jul.30 2018 18:47 PM
U.S. biopharmaceutical firm plans to hold 5.9% of cancer-drug developer to market new treatments in Europe and America
Jul.7 2017 18:44 PM
- Jun 16, 2025 02:54 PM
- Jun 16, 2025 02:53 PM
- Jun 16, 2025 02:52 PM
MOST POPULAR
- 1Cover Story: Chinese Medicine Injections Face Rigorous Regulation for the First Time
- 2France to Receive New Panda Pair Under Renewed 10-Year Deal With China
- 3Wingtech Rebuts Nexperia Claims as Control Fight Threatens Global Chip Supply
- 4 China Flu Cases Surge to Highest Level Since 2022
- 5BYD Overhauls Payment System as China Tightens Oversight
Sign in with Google
Sign in with Facebook
Sign in with 财新